Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Kyverna Therapeutics, Inc. ( (KYTX) ) is now available.
On December 15, 2025, Kyverna Therapeutics announced positive topline data from its Phase 2 trial of mivocabtagene autoleucel (miv-cel) for stiff person syndrome (SPS), showing statistically significant clinical benefits. This data positions miv-cel as a potential first and only approved therapy for SPS, highlighting its transformative impact in the autoimmune disease space and paving the way for a Biologics License Application submission expected in the first half of 2026.
The most recent analyst rating on (KYTX) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.
Spark’s Take on KYTX Stock
According to Spark, TipRanks’ AI Analyst, KYTX is a Underperform.
Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company’s technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock’s performance.
To see Spark’s full report on KYTX stock, click here.
More about Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of CAR T-cell therapies. Its primary product is mivocabtagene autoleucel (miv-cel), a fully human, autologous CD19 CAR T-cell therapy with CD28 co-stimulation, aimed at treating autoimmune diseases such as stiff person syndrome.
Average Trading Volume: 708,589
Technical Sentiment Signal: Buy
Current Market Cap: $384.5M
See more insights into KYTX stock on TipRanks’ Stock Analysis page.